<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004146</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-03011</org_study_id>
    <secondary_id>NCI-2012-03011</secondary_id>
    <secondary_id>CDR67378</secondary_id>
    <secondary_id>NABTT-9904</secondary_id>
    <secondary_id>NABTT-9904</secondary_id>
    <secondary_id>U01CA062475</secondary_id>
    <nct_id>NCT00004146</nct_id>
  </id_info>
  <brief_title>Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM</brief_title>
  <official_title>Phase II Clinical and Pharmacologic Study of Radiation Therapy and CAI (Carboxy-Amido Triazole) in Adults With Newly Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop
      growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining
      radiation therapy with chemotherapy may kill more tumor cells. Phase II trial to study the
      effectiveness of carboxyamidotriazole plus radiation therapy in treating patients who have
      newly diagnosed supratentorial glioblastoma multiforme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate overall survival rate in patients administered CAI (carboxyamidotriazole) and
      radiation therapy to adults with newly diagnosed glioblastoma multiforme.

      II. To determine the toxicity of CAI when combined with cranial irradiation. III. To estimate
      correlations between pharmacokinetic parameters, including steady state CAI concentration,
      with toxicity and/or drug activity in this patient population.

      IV. To estimate duration of disease free progression with this treatment regime.

      OUTLINE: This is a multicenter study.

      Patients receive induction therapy consisting of radiotherapy once daily 5 days a week plus
      oral carboxyamidotriazole once daily for 6 weeks followed by carboxyamidotriazole alone daily
      for 4 weeks. Patients continue on oral carboxyamidotriazole once daily as maintenance therapy
      in the absence of disease progression or unacceptable toxicity. Patients are followed monthly
      for survival.

      PROJECTED ACCRUAL: A total of 54 patients will be accrued for this study over 1.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>approximately 30 months</time_frame>
    <description>estimated period of time event assessed 30 months. event assessed from time of histological diagnosis to death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity of CAI When Combined With RT</measure>
    <time_frame>pts were reviewed for toxicity while on treatement - median time of 2 months</time_frame>
    <description>patients who experienced a grade 3 or higher event considered at least possibly related to CAI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation Between PK CAI and Toxicity in This pt Population</measure>
    <time_frame>during treatment</time_frame>
    <description>PK paramenters including steady state CAI concentrations with toxicity/or drug activity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (RT and CAI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive induction therapy consisting of radiotherapy once daily 5 days a week plus oral carboxyamidotriazole once daily for 6 weeks followed by carboxyamidotriazole alone daily for 4 weeks. Patients continue on oral carboxyamidotriazole once daily as maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for survival.
Other: pharmacological study, radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiotherapy</description>
    <arm_group_label>Treatment (RT and CAI)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboxyamidotriazole</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (RT and CAI)</arm_group_label>
    <other_name>CAI</other_name>
    <other_name>carboxyamido-triazole</other_name>
    <other_name>carboxyaminoimidazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (RT and CAI)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed supratentorial grade IV astrocytoma
             (glioblastoma multiforme)

          -  Patients must have measurable or non-measurable tumor on the post operative,
             pretreatment MRI/CT scan (within two weeks of starting treatment)

          -  Patients must not have received prior radiation therapy, chemotherapy, hormonal
             therapy, immunotherapy or therapy with biologic agents (including immunotoxins,
             immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins,
             TIL, LAK or gene therapy), or hormonal therapy for their brain tumor; glucocorticoid
             therapy is allowed

          -  Patients must have recovered from the immediate post-operative period and be
             maintained on a stable steroid regimen (no increase for the last five days)

          -  Absolute neutrophil count &gt;= 1500/mm^3

          -  Platelets &gt;= 100,000/mm^3

          -  Hemoglobin concentration &gt;= 9.0 g/dl

          -  Creatinine =&lt; 1.7mg/dL

          -  Total bilirubin =&lt; 1.2 mg/dl

          -  Transaminases =&lt; 2 times above the upper limits of the institutional normal

          -  Estimated life expectancy greater than 2 months

          -  Patients must give informed consent and understand the investigational nature of this
             study and its potential risks and benefits

          -  Patients, if female and of childbearing potential must have a negative serum beta-hCG
             test and must not be breast feeding; all patients with the potential for pregnancy
             should be counseled and requested to follow acceptable birth control methods to avoid
             conception

          -  Patients must have a Karnofsky performance status of &gt;= 60%

          -  No other serious concurrent infection or other medical illness should be present which
             would jeopardize the ability of the patient to receive the drug outlined in this
             protocol with reasonable safety

          -  Patients must have no concurrent malignancy except curatively treated basal or
             squamous cell carcinoma of the skin or carcinoma in situ; patients with prior
             malignancies must be disease-free for &gt;= five years

        Exclusion Criteria:

          -  Patients must be able to comply with prescribed medical care

          -  Prior therapy for the brain tumor (except surgery)

          -  Prior treatment with antineoplastic agents, including CAI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Mikkelsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New Approaches to Brain Tumor Therapy Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylavania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>June 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2004</study_first_posted>
  <results_first_submitted>March 13, 2015</results_first_submitted>
  <results_first_submitted_qc>May 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 8, 2015</results_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboxyamido-triazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between March and October of 2000 55 patients(pts) were accrued from outpatient clinics throughout ABTC(Adult Brain Tumor Consortium) consortium clinics</recruitment_details>
      <pre_assignment_details>pts had to have confirmed GBM (Glioblastoma) and be untreated except for biopsy or surgery and corticosteroids.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CAI With RT - Arm 1</title>
          <description>CAI with RT
carboxyamidotriazole :
CAI : CAI 250 mg PO plus RT followed by 4wks CAI alone followed by 8wks CAI then MRI if stable or better continue until progression and then follow for survival
radiation therapy :</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CAI With RT - Arm 1</title>
          <description>CAI with RT
carboxyamidotriazole :
CAI : CAI 250 mg PO plus RT followed by 4wks CAI alone followed by 8wks CAI then MRI if stable or better continue until progression and then follow for survival
radiation therapy :</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="31.0" upper_limit="79.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status</title>
          <description>performance status is an attempt to quantify patients' general well-being and activities of daily life. The scale is in intervals of 10. 100 being normal and 0 dead. For ABTC studies you had to have a KPS of at least 60 (Requires occasional assistance, but is able to care for most of his personal needs) to be eligible for the study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Performance Status 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Performance Status 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Performance Status 80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Performance Status 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Performance Status 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival Rate</title>
        <description>estimated period of time event assessed 30 months. event assessed from time of histological diagnosis to death</description>
        <time_frame>approximately 30 months</time_frame>
        <population>intent to treat pt population. time from histological diagnosis to death.</population>
        <group_list>
          <group group_id="O1">
            <title>CAI With RT - Arm 1</title>
            <description>CAI with RT
carboxyamidotriazole :
CAI : CAI 250 mg PO plus RT followed by 4wks CAI alone followed by 8wks CAI then MRI if stable or better continue until progression and then follow for survival
radiation therapy :</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Rate</title>
          <description>estimated period of time event assessed 30 months. event assessed from time of histological diagnosis to death</description>
          <population>intent to treat pt population. time from histological diagnosis to death.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="8.5" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>the study design is to detect 30% reduction in hazard of deaths with 78% power at one side alpha level of 0.10. Overall survial time was calculated from time of histological diagnosis until time of death from any event.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Toxicity of CAI When Combined With RT</title>
        <description>patients who experienced a grade 3 or higher event considered at least possibly related to CAI</description>
        <time_frame>pts were reviewed for toxicity while on treatement - median time of 2 months</time_frame>
        <population>pts were treated for a median time of 2 months (23 days to 46 months). patients who experienced a grade 3 or higher event considered at least possibly related to CAI</population>
        <group_list>
          <group group_id="O1">
            <title>CAI With RT - Arm 1</title>
            <description>CAI with RT
carboxyamidotriazole :
CAI : CAI 250 mg PO plus RT followed by 4wks CAI alone followed by 8wks CAI then MRI if stable or better continue until progression and then follow for survival
radiation therapy :</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity of CAI When Combined With RT</title>
          <description>patients who experienced a grade 3 or higher event considered at least possibly related to CAI</description>
          <population>pts were treated for a median time of 2 months (23 days to 46 months). patients who experienced a grade 3 or higher event considered at least possibly related to CAI</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between PK CAI and Toxicity in This pt Population</title>
        <description>PK paramenters including steady state CAI concentrations with toxicity/or drug activity</description>
        <time_frame>during treatment</time_frame>
        <population>50 subjects had PK samples for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>CAI With RT + Enzyme Inducing Anticonvulsants</title>
            <description>CAI with RT
carboxyamidotriazole :
CAI : CAI 250 mg PO plus RT followed by 4wks CAI alone followed by 8wks CAI then MRI if stable or better continue until progression and then follow for survival
radiation therapy :</description>
          </group>
          <group group_id="O2">
            <title>CAI With RT Without Enzyme Inducing Anticonvulsants</title>
            <description>CAI with RT
carboxyamidotriazole :
CAI : CAI 250 mg PO plus RT followed by 4wks CAI alone followed by 8wks CAI then MRI if stable or better continue until progression and then follow for survival
radiation therapy :</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between PK CAI and Toxicity in This pt Population</title>
          <description>PK paramenters including steady state CAI concentrations with toxicity/or drug activity</description>
          <population>50 subjects had PK samples for analysis</population>
          <units>ug/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.22"/>
                    <measurement group_id="O2" value="4.06" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE were collected while patients were on active treatment and for 30 days following treatment. pts were on active treatment for a median time of 2 months (23 days - 46 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>CAI with RT
carboxyamidotriazole :
CAI : CAI 250 mg PO plus RT followed by 4wks CAI alone followed by 8wks CAI then MRI if stable or better continue until progression and then follow for survival
radiation therapy :</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>reversible vision loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>hemorrhage-other</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperuricemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stuart A Grossman</name_or_title>
      <organization>Adult Brain Tumor Consortium</organization>
      <phone>410-955-3657</phone>
      <email>jfisher@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

